Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
165,184,059
-
Share change
-
+33,803,300
-
Total reported value
-
$384,891,280
-
Put/Call ratio
-
118%
-
Price per share
-
$2.33
-
Number of holders
-
169
-
Value change
-
+$75,138,227
-
Number of buys
-
90
-
Number of sells
-
58
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2024
As of 30 Jun 2024,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
165,184,059 shares.
The largest 10 holders included
FMR LLC, TPG GP A, LLC, BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, Capital World Investors, PRICE T ROWE ASSOCIATES INC /MD/, PRIMECAP MANAGEMENT CO/CA/, Woodline Partners LP, and JPMORGAN CHASE & CO.
This page lists
169
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.